Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
As lymphoid organs are the major reservoir of human immunodeficiency virus type 1 (HIV-1), the rates at which HIV-1 RNA decreases from the plasma and from a series of lymph node biopsies from 4 patients treated with a combination of zidovudine, didanosine, and lamivudine were measured. The concentrations of HIV-1 RNA in the plasma and in lymph nodes declined exponentially, with mean half-lives of 1.88 +/- 0.86 days for plasma and 6.01 +/- 3.44 days for lymph nodes. These data show that most of the HIV-1 in lymphoid organs is due to the infection of new cells and demonstrate that a triple-drug combination is able to target this compartment.
Lafeuillade
A
A
Department of Infectious Diseases, General Hospital, Toulon, France.
Poggi
C
C
Profizi
N
N
Tamalet
C
C
Costes
O
O
D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy / Q000379:methods*; D016049:Didanosine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D007700:Kinetics; D019259:Lamivudine; D008198:Lymph Nodes / Q000821:virology*; D012367:RNA, Viral / Q000302:isolation & purification; D014766:Viremia; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
D000998:Antiviral Agents; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine